<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Acta Naturae</journal-id><journal-title-group><journal-title xml:lang="en">Acta Naturae</journal-title><trans-title-group xml:lang="ru"><trans-title>Acta Naturae</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-8251</issn><publisher><publisher-name xml:lang="en">Acta Naturae Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">11753</article-id><article-id pub-id-type="doi">10.32607/actanaturae.11753</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Research Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Экспериментальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Comprehensive Analysis of Stromal and Serum Markers in Gastric Cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Комплексный анализ стромальных и сывороточных маркеров при раке желудка</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kovaleva</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Ковалева</surname><given-names>Ольга В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ovkovaleva@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Podlesnaya</surname><given-names>Polina A.</given-names></name><name xml:lang="ru"><surname>Подлесная</surname><given-names>Полина А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>polina.pod@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chang</surname><given-names>Viktor L.</given-names></name><name xml:lang="ru"><surname>Чанг</surname><given-names>Виктор Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ken_baxter@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ognerubov</surname><given-names>Nikolai A.</given-names></name><name xml:lang="ru"><surname>Огнерубов</surname><given-names>Николай А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ognerubovn.a@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gratchev</surname><given-names>Alexei N.</given-names></name><name xml:lang="ru"><surname>Грачев</surname><given-names>Алексей Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alexei.gratchev@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozlov</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Козлов</surname><given-names>Н. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ovkovaleva@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stilidi</surname><given-names>Ivan S.</given-names></name><name xml:lang="ru"><surname>Стилиди</surname><given-names>Иван С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ronc@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kushlinskii</surname><given-names>Nikolai E.</given-names></name><name xml:lang="ru"><surname>Кушлинский</surname><given-names>Николай Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>biochimia@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russian Federation</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Medical Institute of G.P. Derzhavin Tambov State University</institution></aff><aff><institution xml:lang="ru">Тамбовский государственный университет им. Г.Р. Державина Министерства образования и науки</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-12-26" publication-format="electronic"><day>26</day><month>12</month><year>2022</year></pub-date><volume>14</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>75</fpage><lpage>83</lpage><history><date date-type="received" iso-8601-date="2022-06-14"><day>14</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-10-21"><day>21</day><month>10</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Kovaleva O., Podlesnaya P., Chang V., Ognerubov N., Gratchev A., Stilidi I., Kushlinskii N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Ковалева О., Подлесная П., Чанг В., Огнерубов Н., Грачев А., Стилиди И., Кушлинский Н.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Kovaleva O., Podlesnaya P., Chang V., Ognerubov N., Gratchev A., Stilidi I., Kushlinskii N.</copyright-holder><copyright-holder xml:lang="ru">Ковалева О., Подлесная П., Чанг В., Огнерубов Н., Грачев А., Стилиди И., Кушлинский Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://actanaturae.ru/2075-8251/article/view/11753">https://actanaturae.ru/2075-8251/article/view/11753</self-uri><abstract xml:lang="en"><p>A comprehensive analysis of the cell phenotype of the inflammatory infiltrate of the tumor stroma represents a promising area of molecular oncology. The study of not only soluble forms of various immunoregulatory molecules, but also their membrane-bound forms is also considered highly relevant. We performed a comprehensive analysis of tissue and circulating forms of the PD-1 and PD-L1 proteins, as well as macrophage and B-cell markers in the tumor stroma of gastric cancer, to assess their clinical and prognostic significance. The tumor and blood plasma samples from 63 gastric cancer patients were studied using ELISA and immunohistochemistry. Malignant gastric tumors were shown to be strongly infiltrated by B-cells, and their number was comparable to that of macrophages. For PU.1 expression, an association with tumor size was observed; i.e., larger tumors were characterized by fewer PU.1+ infiltrating cells (<italic>p</italic> = 0.005). No clinical significance was found for CD20 and CD163, but their numbers were higher at earlier stages of the disease and in the absence of metastases. It was also demonstrated that the PD-L1 content in tumor cells was not associated with the clinical and morphological characteristics of GC. At the same time, PD-L1 expression in tumor stromal cells was associated with the presence of distant metastases. The analysis of the prognostic significance of all the markers studied demonstrated that CD163 was statistically significantly associated with a poor prognosis for the disease (<italic>p</italic> = 0.019). In addition, PD-L1 expression in tumor cells tended to indicate a favorable prognosis (<italic>p</italic> = 0.122). The results obtained in this work indicate that the study of soluble and tissue markers of tumor stroma is promising in prognosticating the course of GC. The search for combinations of markers seems to be highly promising, with their comprehensive analysis capable of helping personalize advanced antitumor therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Комплексный анализ фенотипа клеток воспалительного инфильтрата опухолевой стромы является перспективным направлением молекулярной онкологии. Также крайне актуальным представляется изучение не только мембраносвязанных форм различных молекул, связанных с иммунной регуляцией, но и их растворимых форм. Проведен комплексный анализ тканевых и циркулирующих форм белков PD-1 и PD-L1, а также макрофагов и В-клеток стромы злокачественных опухолей желудка для оценки их клинической и прогностической значимости. Проведен иммуноферментный и иммуногистохимический анализ 63 образцов опухолей и плазмы крови от больных раком желудка. Показано, что злокачественные опухоли желудка сильно инфильтрированы В-клетками, количество которых сравнимо с содержанием макрофагов. Обнаружена ассоциация экспрессии PU.1 с размером опухоли, а именно, опухоли большего размера содержат меньше PU.1+ инфильтрирующих клеток (<italic>p</italic> = 0.005). Не выявлено клинической значимости CD20+ и CD163+ клеток, однако их количество в строме было больше на более ранних стадиях заболевания и при отсутствии метастазов. Показано также, что содержание PD-L1 в опухолевых клетках не ассоциировано с клиническими и морфологическими характеристиками рака желудка, в то время как экспрессия PD-L1 в стромальных клетках опухоли ассоциирована с наличием отдаленных метастазов. Анализ прогностической значимости исследованных маркеров показал, что CD163 статистически значимо ассоциирован с неблагоприятным прогнозом данного заболевания (<italic>p</italic> = 0.019). Отмечена также тенденция к благоприятному прогнозу в случае экспрессии PD-L1 в опухолевых клетках (<italic>p</italic> = 0.122). Полученные нами результаты свидетельствуют о перспективности изучения растворимых и тканевых маркеров опухолевой стромы для прогнозирования течения рака желудка. Актуальным представляется поиск комбинаций маркеров, комплексный анализ которых поможет персонализировать современную противоопухолевую терапию.</p></trans-abstract><kwd-group xml:lang="en"><kwd>gastric cancer</kwd><kwd>PD-1</kwd><kwd>PD-L1</kwd><kwd>stroma</kwd><kwd>prognosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак желудка</kwd><kwd>PD-1</kwd><kwd>PD-L1</kwd><kwd>строма</kwd><kwd>прогноз</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">РФФИ</institution></institution-wrap><institution-wrap><institution xml:lang="en">Russian Foundation for Basic Research</institution></institution-wrap></funding-source><award-id>20-015-00479</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. // CA Cancer J. Clin. 2018. V. 68. № 6. P. 394–424.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Gonzalez C.A., Sala N., Rokkas T. // Helicobacter. 2013. V. 18 Suppl 1. P. 34–38.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Nomura A., Grove J.S., Stemmermann G.N., Severson R.K. // Cancer Res. 1990. V. 50. № 21. P. 7084.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Brooks-Wilson A.R., Kaurah P., Suriano G., Leach S., Senz J., Grehan N., Butterfield Y.S., Jeyes J., Schinas J., Bacani J., et al. // J. Med. Genet. 2004. V. 41. № 7. P. 508–517.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cunningham D., Starling N., Rao S., Iveson T., Nicolson M., Coxon F., Middleton G., Daniel F., Oates J., Norman A.R., et al. // N. Engl. J. Med. 2008. V. 358. № 1. P. 36–46.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bang Y.J., van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., et al. // Lancet. 2010. V. 376. № 9742. P. 687–697.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Wilke H., Muro K., van Cutsem E., Oh S.C., Bodoky G., Shimada Y., Hironaka S., Sugimoto N., Lipatov O., Kim T.Y., et al. // Lancet Oncol. 2014. V. 15. № 11. P. 1224–1235.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zhang H., Yue R., Zhao P., Yu X., Li J., Ma G., Tang J., Zhang L., Feng L., Sun L., et al. // Tumour Biol. 2017. V. 39. № 6. P. 1010428317705747. doi: 10.1177/1010428317705747</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hu H.T., Ai X., Lu M., Song Z., Li H. // Exp. Cell. Res. 2019. V. 384. № 2. P. 111652.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kovaleva O.V., Rashidova M.A., Samoilova D.V., Podlesnaya P.A., Mochalnikova V.V., Gratchev A. // Anal. Cell. Pathol. (Amst.). 2020. V. 2020. P. 5424780.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Xu Y., Gu S., Bi Y., Qi X., Yan Y., Lou M. // Oncol. Lett. 2018. V. 15. № 3. P. 3753–3759.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Lin J., Liu W., Luan T., Yuan L., Jiang W., Cai H., Yuan W., Wang Y., Zhang Q., Wang L. // Oncol. Lett. 2017. V. 14. № 6. P. 8220–8226.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kovaleva O.V., Rashidova M.A., Samoilova D.V., Podlesnaya P.A., Mochalnikova V.V., Gratchev A.N. // Bull. Exp. Biol. Med. 2021. V. 170. № 4. P. 489–492.</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Kovaleva O.V., Gratchev A.N., Podlesnaya P.A., Rashidova M.A., Samoilova D.V., Sokolov N Yu., Mamedli Z.Z., Kudlay D.A., Kushlinskii N.E. // Clinical and experimantal morphology. 2021. V. 10. № 2. P. 32–39. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Ковалева О.В., Грачев А.Н., Подлесная П.А., Рашидова М.А., Самойлова Д.В., Соколов Н.Ю., Мамедли З.З., Кудлай Д.А., Кушлинский Н.Е. // Клин. эксп. морфол. 2021. Т. 10. № 2. C. 32–39.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><mixed-citation>Huang J., Chen W., Jie Z., Jiang M. // Front. Oncol. 2022. V. 12. P. 820568.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. // Trends Immunol. 2002. V. 23. № 11. P. 549–555.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kovaleva O., Podlesnaya P., Rashidova M., Samoilova D., Petrenko A., Mochalnikova V., Kataev V., Khlopko Y., Plotnikov A., Gratchev A. // Biomedicines. 2021. V. 9. № 7. P. 743.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Koelzer V.H., Canonica K., Dawson H., Sokol L., Karamitopoulou-Diamantis E., Lugli A., Zlobec I. // Oncoimmunology. 2016. V. 5. № 4. P. e1106677.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Huang Y.K., Wang M., Sun Y., Di Costanzo N., Mitchell C., Achuthan A., Hamilton J.A., Busuttil R.A., Boussioutas A. // Nat. Commun. 2019. V. 10. № 1. P. 3928.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Svensson M.C., Svensson M., Nodin B., Borg D., Hedner C., Hjalmarsson C., Leandersson K., Jirstrom K. // J. Innate Immun. 2022. № 3. P. 1–14.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zhu Q., Wu X., Tang M., Wu L. // Medicine (Baltimore). 2020. V. 99. № 17. P. e19839.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Zhang W.J., Zhou Z.H., Guo M., Yang L.Q., Xu Y.Y., Pang T.H., Gao S.T., Xu X.Y., Sun Q., Feng M., et al. // J. Cancer. 2017. V. 8. № 3. P. 363–370.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Harada K., Dong X., Estrella J.S., Correa A.M., Xu Y., Hofstetter W.L., Sudo K., Onodera H., Suzuki K., Suzuki A., et al. // Gastric Cancer. 2018. V. 21. № 1. P. 31–40.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Sjoberg E., Frodin M., Lovrot J., Mezheyeuski A., Johansson M., Harmenberg U., Egevad L., Sandstrom P., Ostman A. // Br. J. Cancer. 2018. V. 119. № 7. P. 840–846.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Mahmoud S.M., Lee A.H., Paish E.C., Macmillan R.D., Ellis I.O., Green A.R. // Breast Cancer Res. Treat. 2012. V. 132. № 2. P. 545–553.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Shi J.Y., Gao Q., Wang Z.C., Zhou J., Wang X.Y., Min Z.H., Shi Y.H., Shi G.M., Ding Z.B., Ke A.W., et al. // Clin. Cancer Res. 2013. V. 19. № 21. P. 5994–6005.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Lundgren S., Berntsson J., Nodin B., Micke P., Jirstrom K. // J. Ovarian Res. 2016. V. 9. P. 21.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Berntsson J., Nodin B., Eberhard J., Micke P., Jirstrom K. // Int. J. Cancer. 2016. V. 139. № 5. P. 1129–1139.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Dong J., Li J., Liu S.M., Feng X.Y., Chen S., Chen Y.B., Zhang X.S. // Med. Oncol. 2013. V. 30. № 1. P. 442.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Meier A., Nekolla K., Hewitt L.C., Earle S., Yoshikawa T., Oshima T., Miyagi Y., Huss R., Schmidt G., Grabsch H.I. // J. Pathol. Clin. Res. 2020. V. 6. № 4. P. 273–282.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Gu L., Chen M., Guo D., Zhu H., Zhang W., Pan J., Zhong X., Li X., Qian H., Wang X. // PLoS One. 2017. V. 12. № 8. P. e0182692.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Kim J.W., Nam K.H., Ahn S.H., Park D.J., Kim H.H., Kim S.H., Chang H., Lee J.O., Kim Y.J., Lee H.S., et al. // Gastric Cancer. 2016. V. 19. № 1. P. 42–52.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Boger C., Behrens H.M., Mathiak M., Kruger S., Kalthoff H., Rocken C. // Oncotarget. 2016. V. 7. № 17. P. 24269–24283.</mixed-citation></ref></ref-list></back></article>
